Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$3.44
+0.4%
$3.50
$3.07
$6.66
$203.03M0.511.04 million shs598,633 shs
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
$1.93
+2.4%
$1.97
$0.40
$2.66
$259.03M0.41818,566 shs482,823 shs
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
$2.26
-1.1%
$2.25
$1.42
$5.50
$66.00M1.26707,519 shs1.51 million shs
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$3.14
-2.0%
$2.89
$1.18
$3.88
$199.26M1.08999,363 shs405,264 shs
The 10 Best AI Stocks to Own in 2026 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.00%-0.85%+1.16%-14.29%-28.10%
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
0.00%+6.29%-14.21%-9.63%+217.13%
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
0.00%+7.04%-11.82%-23.52%+24.21%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
0.00%+2.62%+1.95%+78.86%+78.86%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$3.44
+0.4%
$3.50
$3.07
$6.66
$203.03M0.511.04 million shs598,633 shs
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
$1.93
+2.4%
$1.97
$0.40
$2.66
$259.03M0.41818,566 shs482,823 shs
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
$2.26
-1.1%
$2.25
$1.42
$5.50
$66.00M1.26707,519 shs1.51 million shs
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$3.14
-2.0%
$2.89
$1.18
$3.88
$199.26M1.08999,363 shs405,264 shs
The 10 Best AI Stocks to Own in 2026 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.00%-0.85%+1.16%-14.29%-28.10%
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
0.00%+6.29%-14.21%-9.63%+217.13%
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
0.00%+7.04%-11.82%-23.52%+24.21%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
0.00%+2.62%+1.95%+78.86%+78.86%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
2.00
HoldN/AN/A
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
2.67
Moderate Buy$4.60138.96% Upside
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
2.25
Hold$13.50498.67% Upside
MacroGenics, Inc. stock logo
MGNX
MacroGenics
2.25
Hold$5.4072.25% Upside

Current Analyst Ratings Breakdown

Latest ANVS, ALXO, MGNX, and ACB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/1/2026
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
UpgradeSell (E+)Sell (D-)
4/29/2026
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
DowngradeSell (D-)Sell (E+)
4/20/2026
MacroGenics, Inc. stock logo
MGNX
MacroGenics
Boost Price TargetOverweight$4.00 ➝ $6.00
4/14/2026
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
Reiterated RatingBuy$17.00
4/10/2026
MacroGenics, Inc. stock logo
MGNX
MacroGenics
UpgradeNeutralBuy$3.00 ➝ $9.00
3/19/2026
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
Initiated CoverageOverweight$5.00
3/10/2026
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
Reiterated RatingBuy$4.00
3/10/2026
MacroGenics, Inc. stock logo
MGNX
MacroGenics
Boost Price TargetOverweight$3.00 ➝ $4.00
3/6/2026
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
Initiated CoverageBuy$6.00
2/24/2026
MacroGenics, Inc. stock logo
MGNX
MacroGenics
Reiterated RatingMarket Perform
2/5/2026
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
Boost Price TargetOverweight$3.00 ➝ $4.00
(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$373.12M0.54$0.60 per share5.69$7.78 per share0.44
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
N/AN/AN/AN/A$0.48 per shareN/A
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/AN/AN/AN/A$0.64 per shareN/A
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$149.50M1.33N/AN/A$0.88 per share3.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$1.63M-$1.08N/AN/AN/A-23.46%-0.04%-0.03%6/17/2026 (Estimated)
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
-$101.69M-$1.90N/AN/AN/AN/A-182.01%-113.63%5/14/2026 (Estimated)
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$28.85M-$1.40N/AN/AN/AN/A-159.43%-133.49%5/19/2026 (Estimated)
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$74.62M-$1.17N/AN/AN/A-49.91%-120.19%-29.92%5/12/2026 (Estimated)

Latest ANVS, ALXO, MGNX, and ACB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/19/2026Q1 2026
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$0.3950N/AN/AN/AN/AN/A
5/14/2026Q1 2026
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
-$0.15N/AN/AN/AN/AN/A
5/12/2026Q1 2026
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$0.56N/AN/AN/A$16.29 millionN/A
3/13/2026Q4 2025
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$0.3084-$0.39-$0.0816-$0.39N/AN/A
3/9/2026Q4 2025
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
N/A-$0.42N/A-$0.42N/AN/A
3/9/2026Q4 2025
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$0.42-$0.2241+$0.1959-$0.22$27.81 million$41.23 million
2/27/2026Q4 2025
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
-$0.38-$0.42-$0.04-$0.42N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
N/AN/AN/AN/AN/A
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/AN/AN/AN/AN/A
MacroGenics, Inc. stock logo
MGNX
MacroGenics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.06
3.06
1.48
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
0.17
2.07
2.07
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/A
5.80
5.80
MacroGenics, Inc. stock logo
MGNX
MacroGenics
N/A
5.10
4.92

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
97.97%
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
15.83%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
96.89%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
21.00%
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
20.80%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
13.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,13059.11 million59.10 millionOptionable
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
40134.56 million106.30 millionOptionable
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
329.27 million23.18 millionOptionable
MacroGenics, Inc. stock logo
MGNX
MacroGenics
43063.56 million54.92 millionOptionable

Recent News About These Companies

FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study
MacroGenics: Q4 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$3.44 +0.02 (+0.44%)
As of 03:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

ALX Oncology stock logo

ALX Oncology NASDAQ:ALXO

$1.92 +0.05 (+2.39%)
As of 03:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Annovis Bio stock logo

Annovis Bio NYSE:ANVS

$2.26 -0.03 (-1.10%)
As of 03:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

MacroGenics stock logo

MacroGenics NASDAQ:MGNX

$3.14 -0.07 (-2.03%)
As of 03:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.